TRPM4 in Bladder Cancer: Prognostic Gene Risk Model and Drug Sensitivity Analysis

A 105.1 KB Excel file by Qi Zhao, last updated in April 2026, contains integrated single-cell and transcriptome data for bladder cancer. The data includes 220 candidate genes, a six-gene prognostic risk model, and differential responses for 112 drugs. The study explores the prognostic value of TRPM4 and related genes.

Use Cases

• Validate the six-gene prognostic risk model (UNC93B1, FAM193B, POGLUT3, FBN1, MAP1B, RUNX2) based on the described analysis.
• Analyze immune infiltration patterns based on the 12 identified immune cell types, including naive B cells.
• Investigate drug sensitivity differentials based on the 112 drugs mentioned, such as WZ3105.
• Explore gene set enrichment disparities based on key pathways like the melanoma pathway identified in the study.

Strengths

• Includes a specific six-gene prognostic risk model (UNC93B1, FAM193B, POGLUT3, FBN1, MAP1B, RUNX2).
• Identifies 220 candidate genes from integrated single-cell and transcriptomic analyses.
• Contains drug sensitivity analysis results for 112 drugs.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

Qi Zhao via figshare

Collection Method

Integrative analysis of single-cell and whole-genome transcriptomic data.

Time Range

null

Freshness

Last updated 2026-04-13 05:21:48; freshness should be verified.

Geography

null